Chest
-
Tuberculosis PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Tuberculosis prevelance of patients who were on therapy of tumor necrozing factor antagonists (TNF) was 449/100.000. Here we evaluated the clinical characteristics of our patients who had tuberculosis infection during the therapy of TNF antagonists. ⋯ The following authors have nothing to disclose: Tulin Cagatay, Zuleyha Bingol, Zeynep Yegin, Gulfer Okumus, Esen Kiyan, Orhan Arseven, Feyza Erkan, Ziya Gulbaran, Mustafa Erelel, Turhan Ece, Zeki KilicaslanNo Product/Research Disclosure Information.
-
Surgery Case Report Posters IISESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMINTRODUCTION: Radical chest wall tumor resections result in large chest wall defects that expose intrathoracic organs to injury, risk lung herniation or scapular entrapment, and create flail chest segments that negatively impact respiration. ⋯ The following authors have nothing to disclose: Eric Toloza, Christian Sobky, Jose Pimiento, Joseph Garrett, Effie Pappas-Politis, Jeremiah Deneve, David Kim, David Plank, Paul Smith, Ricardo GonzalezUse of the Synthes MatrixRib Fixation System is not yet approved for fixation onto the thoracic spine.
-
Sleep PostersSESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: AIMS 1-To study the effect of the growth pattern in the treatment of SAHS by a MAD by the use of polysomnographic recordings. 2-To determine the effect of the growth pattern on the position of the hyoid bone in the SAHS treatment by a MAD. ⋯ The following authors have nothing to disclose: Rafael Ecija, Javier Jareño, Alejandro Coca, Inmaculada Sierra, Marta Dominguez, Carlos Gutierrez OrtegaNo Product/Research Disclosure Information.
-
Pulmonary Hypertension Posters IISESSION TYPE: Poster PresentationsPRESENTED ON: Saturday, March 22, 2014 at 01:15 PM - 02:15 PMPURPOSE: Despite the availability of specific treatment, pulmonary arterial hypertension (PAH) remains a devastating and fatal disease. Slovakia has a systemic program of PAH management. Mortality data, however, have been lacking. The aim was to describe the survival in pts with newly diagnosed PAH at a referral centre in Slovakia in the era of targeted treatment and analyse causes of death. ⋯ The following authors have nothing to disclose: Milan Luknar, Branislav Liska, Peter Lesny, Ivan Varga, Peter Solik, Eva GoncalvesovaNo Product/Research Disclosure Information.
-
Cardiovascular Case Report Posters ISESSION TYPE: Case Report PosterPRESENTED ON: Sunday, March 23, 2014 at 01:15 PM - 02:15 PMPURPOSE: Primary pulmonary hypertension is severe and progressive disease with incidence of 1-2 cases / million / annum. Without treatment, survival is 2-3 years. Only 10% survive for 10 years. Co-existence of PPH with Marfanoid Habitus has not been reported till date in any literature or case study.Large series of 120 PPH patients from Mayo clinic by Fuster et al showed thrombotic mechanism by microemboli and plexogenic arteriopathy due to hyper reactive pulmonary arteries by open lung biopsies. ⋯ The following authors have nothing to disclose: Ram k Chopra, Sanesh Garde, Chintan Patel, Dhiraj Jain, Omkar Kajale, Rahul JalanNo Product/Research Disclosure Information.